Navigation Links
Data Presented At Breast Cancer Symposium 2014 Validates Biscayne Pharmaceuticals' GHRH Target In Breast Cancer
Date:9/3/2014

SAN FRANCISCO and MIAMI BEACH, Fla., Sept. 3, 2014 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be featured in a presentation at the American Society of Clinical Oncology's (ASCO) Breast Cancer Symposium 2014. The data will be presented by Biscayne's Medical Director, Norman Block, MD, who is also Clinical Director of the Endocrine, Polypeptide and Cancer Institute at the Veterans Affairs Medical Center in Miami and the L. Austin Weeks Family Professor of Urologic Research at the University of Miami Miller School of Medicine.

Scientists have long known that GHRH, which is made in the brain, releases growth hormone to manage growth and tissue repair in nearby cells. Dr. Andrew V. Schally, a world-renowned drug researcher and Nobel laureate, discovered that other cells throughout the body, including cancer cells, also have receptors for GHRH. Cancer cells contain GHRH receptors and also produce the GHRH hormone, thereby fueling their own growth. Biscayne Pharmaceuticals has licensed rights to Dr. Schally's GHRH discoveries and is developing GHRH antagonists that inhibit tumor growth by binding to and blocking the activity of the GHRH receptors on cancer cells.

Much of the earlier work on GHRH and cancer has been conducted in preclinical models. In the Breast Cancer Symposium 2014 poster presentation1, Dr. Block and his colleagues present data on GHRH using specimens from breast cancer patients. They conclude that the majority of breast cancers, including both primary and metastatic tumors, are GHRH-receptor positive, confirming the validity of GHRH as a potential therapeutic target for new breast cancer drugs.

Dr. Block, who conducts research in collaboration with Dr. Schally, commented, "Extensive studies in preclinical models gave us confidence that GHRH is an important driver of tumor growth and that antagonists of GHRH might have potential as effective anti-cancer agents. This new study using tumor samples from breast cancer patients further confirms the potential relevance of those findings to human disease and supports our goal of rapidly advancing our lead GHRH antagonist into human clinical trials."

Biscayne's GHRH antagonists are in preclinical development for the treatment of cancer. In animal studies, these antagonists have shown promising anti-tumor activity.  The company believes that its GHRH antagonists may have therapeutic potential in many types of tumors, including breast cancer.

  1. Expression of GHRH-R in Primary and Metastatic Mammary Carcinomas. M Nadji, N Block, A V Schally, J Lara, R Michaelson, Suhail M Ali, K Leitzel and A Lipton, General Poster Session B, Board B10, September 5, 2014.

The ASCO Breast Cancer Symposium 2014 is being held September 4-6, 2014 in San Francisco, CA. For more information visit http://breastcasym.org/

About Biscayne PharmaceuticalsBiscayne Pharmaceuticals, Inc. is a privately held biopharmaceutical company discovering and developing novel therapies based on growth hormone-releasing hormone (GHRH) analogs. The company's technology stems from the discoveries of Dr. Andrew V. Schally, a Nobel laureate and pioneering endocrine drug developer. Biscayne's lead compounds include GHRH antagonists in development for the treatment of cancer and GHRH agonists for the repair of cardiac damage in heart disease patients. GHRH analogs may also have utility in other conditions, such as Alzheimer's disease.  Biscayne's technology is licensed from the University of Miami and the company is headquartered in Miami, FL. For more information, visit biscaynepharmaceuticals.com Contacts:Biscayne Pharmaceuticals Corporate:

Media:Jared Mendel

BLL Partners(786) 502-4220

Barbara Lindheiminfo@biscaynepharma.com

(212) 584-2276blindheim@bllbiopartners.com 


'/>"/>
SOURCE Biscayne Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
11. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... ... has joined the company as an Expert Consultant. Mr. Clark was formerly ... and managing the development of small molecule monographs based on analytical methods. ...
(Date:4/27/2016)... ... ... Global Stem Cells Group and the University of Santiago Biotechnology Lab have ... for potential stem cell protocol management for 2016 – 2020. , In 2015, ... establish a working agenda and foster initiatives to promote stem cell research and development ...
(Date:4/26/2016)... Redwood City, CA (PRWEB) , ... April 26, ... ... company for healthcare, today announced that Ardy Arianpour has joined the company as ... 14 years of experience bringing innovative genomic technologies to market, was most recently ...
(Date:4/26/2016)... ... ... This unique "Fertility Happy Hour" event will be held at The Saguaro Hotel ... on female fertility and the reproductive technologies that are empowering a new generation of ... The Arizona Center, will give a short presentation and answer questions about age ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):